+966 568813716 seragadel@gmail.com

The Blog

Home / Page 34
03
Dec
2016
Paliperidone palmitate (Invega Sustenna®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Paliperidone palmitate (Invega Sustenna®) is an extended-release injectable second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-approved indications Treatment of schizophrenia Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants Dosage A. Schizophrenia Initiation (IM deltoid): Administer 234 mg […]

Read More

03
Dec
2016
Extended Release Olanzapine (Zyprexa Relprevv®)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Extended Release Olanzapine (Zyprexa Relprevv®) is a long-acting, second-generation (atypical), injectable antipsychotic. Here is basic information about this medication. FDA-approved indications Schizophrenia Dosage Recommended dosing of extended release olanzapine based on correspondence to oral olanzapine doses A. First 8 weeks of treatment a) Target oral dose 10 mg/day: 210 […]

Read More

03
Dec
2016
Haloperidol (Haldol® Decanoate)
Posted On December 3, 2016  By Dr.Adel Serag  And has No Comment

Haldol® Decanoate is a brand name of a depot formulation of haloperidol which is a first-generation (“typical”) antipsychotic. Here is basic information about this medication. FDA-approved indications Treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy Dosage A. Initial dosage (given by deep IM injection […]

Read More

01
Dec
2016
Top 10 Meditation tools
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

Read More

01
Dec
2016
Ziprasidone (Geodon®)
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

Ziprasidone (US brand name Geodon® and generic) is a second-generation (“atypical”) antipsychotic. FDA-approved indications A. As an oral formulation 1. Schizophrenia 2. Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder 3. Maintenance treatment of bipolar I disorder as an adjunct […]

Read More

01
Dec
2016
Lurasidone (Latuda®)
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

Lurasidone or Latuda® is a second-generation antipsychotic, manufactured by Sunovion and introduced in the US in 2010 for the acute treatment of schizophrenia. Note: This page and its related pages contain the full text of the chapter on lurasidone (Latuda) in my book, The Latest Antidepressants. This webpage […]

Read More

01
Dec
2016
Iloperidone (Fanapt®): Basic Information
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

Iloperidone (US brand name Fanapt®) is a second-generation (“atypical”) antipsychotic. FDA-approved indications Treatment of adults with schizophrenia Dosage Starting: 1 mg twice daily Target: 6–12 mg twice daily (achieved by dose increments of 1–2 mg twice daily) Maximum: 12 mg twice daily (24 mg/day) Please refer […]

Read More

01
Dec
2016
Clozapine (Clozaril®)
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

Clozapine (US brand names Clozaril®, Fazaclo® ODT, Versacloz®, and generic) is a second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. Treatment resistant schizophrenia 2. Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder Dosage Starting: 12.5 mg once or twice daily, with or without […]

Read More

01
Dec
2016
Cariprazine (Vraylar®)
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

Cariprazine (Vraylar®) is a second-generation (atypical) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. Schizophrenia 2. Acute treatment of manic or mixed episodes associated with bipolar I disorder. Dosage Schizophrenia Starting: 1.5 mg/day Recommended: 1.5–6 mg/day Bipolar Mania Starting: 1.5 mg/day Recommended: 3–6 mg/day […]

Read More

01
Dec
2016
Brexpiprazole (Rexulti®)
Posted On December 1, 2016  By Dr.Adel Serag  And has No Comment

The United States Food and Drug Administration (FDA) approved   brexpiprazole (brand name “Rexulti®”) in July 2015 for two indications:   the treatment of schizophrenia and as adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Rexulti® is manufactured by Otsuka Pharmaceutical Company Ltd and co-marketed with […]

Read More

Page 34 of 90